BioCentury on BioBusiness,
Emerging Company Profile
The immune system cannot ignore nanoparticle vaccines from Selecta Biosciences
Related tables, figures and sidebars
Selecta: Impossible to Ignore
Monday, April 12, 2010
Selecta Biosciences Inc. is developing synthetic nanoparticle vaccines designed
to mimic invading pathogens in order to elicit an immune response against
molecules that would ordinarily be ignored. The company believes its vaccines
could be safer, more efficacious and applicable to more diseases than
Executive Chairman Robert Bratzler told BioCentury Selecta's
targeted Synthetic Vaccine Particle (tSVP) platform combines a pair of
discoveries made by the company's three scientific founders, Ulrich von Andrian
and Omid Farokhzad at Harvard
Medical School, and Robert Langer at Massachusetts
Institute of Technology.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]